Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 2
1956 1
1960 2
1961 1
1968 2
1969 1
1970 1
1971 1
1973 1
1974 2
1975 2
1976 3
1977 1
1978 3
1979 2
1980 1
1981 4
1982 3
1983 5
1984 4
1986 2
1987 3
1988 3
1989 3
1990 6
1991 1
1992 6
1993 4
1994 6
1995 4
1996 3
1997 6
1998 5
1999 7
2000 3
2001 3
2002 2
2003 2
2006 1
2007 1
2008 1
2009 3
2010 5
2011 9
2012 5
2013 6
2014 6
2015 1
2016 3
2017 4
2018 7
2019 10
2020 14
2021 13
2022 16
2023 15
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9. Lancet. 2020. PMID: 33278935 Clinical Trial.
Oncogenic ETS Factors in Prostate Cancer.
Nicholas TR, Strittmatter BG, Hollenhorst PC. Nicholas TR, et al. Adv Exp Med Biol. 2019;1210:409-436. doi: 10.1007/978-3-030-32656-2_18. Adv Exp Med Biol. 2019. PMID: 31900919 Review.
Role of Disease Progression Models in Drug Development.
Barrett JS, Nicholas T, Azer K, Corrigan BW. Barrett JS, et al. Among authors: nicholas t. Pharm Res. 2022 Aug;39(8):1803-1815. doi: 10.1007/s11095-022-03257-3. Epub 2022 Apr 11. Pharm Res. 2022. PMID: 35411507 Free PMC article. Review.
Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study.
Millar PR, Gordon BA, Luckett PH, Benzinger TLS, Cruchaga C, Fagan AM, Hassenstab JJ, Perrin RJ, Schindler SE, Allegri RF, Day GS, Farlow MR, Mori H, Nübling G; Dominantly Inherited Alzheimer Network; Bateman RJ, Morris JC, Ances BM. Millar PR, et al. Elife. 2023 Jan 6;12:e81869. doi: 10.7554/eLife.81869. Elife. 2023. PMID: 36607335 Free PMC article.
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data.
Conrado DJ, Duvvuri S, Geerts H, Burton J, Biesdorf C, Ahamadi M, Macha S, Hather G, Francisco Morales J, Podichetty J, Nicholas T, Stephenson D, Trame M, Romero K, Corrigan B; Drug Development Tools in the Alzheimer Disease Continuum (DDT-AD) Working Group. Conrado DJ, et al. Among authors: nicholas t. Clin Pharmacol Ther. 2020 Apr;107(4):796-805. doi: 10.1002/cpt.1782. Epub 2020 Mar 11. Clin Pharmacol Ther. 2020. PMID: 31955409 Review.
230 results